04.08.2016 RHÖN-KLINIKUM AG  DE0007042301

DGAP-News: RHÖN-KLINIKUM AG: Interim Report for the First Six Months of 2016:RHÖN-KLINIKUM AG Continues its Strong Growth - Strategic Focus on Network Medicine and Digitalisation


 
DGAP-News: RHÖN-KLINIKUM AG / Key word(s): Half Year Results RHÖN-KLINIKUM AG: Interim Report for the First Six Months of 2016:RHÖN-KLINIKUM AG Continues its Strong Growth - Strategic Focus on Network Medicine and Digitalisation 04.08.2016 / 06:59 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Press Release Interim Report for the First Six Months of 2016: RHÖN-KLINIKUM AG Continues its Strong Growth - Strategic Focus on Network Medicine and Digitalisation - 414,403 patients treated - Revenues stand at Euro 590.6 million - EBITDA in the amount of Euro 103.4 million includes dissolving provisions of Euro 41 million - Outlook for 2016 remains unchanged: Revenues between Euro 1.17 billion and Euro 1.20 billion, EBITDA between Euro 155 million and Euro 165 million Bad Neustadt / Saale, 4th August 2016 RHÖN-KLINIKUM AG continued its strong growth during the first six months of the current financial year 2016. In the first half-year a total of 414,403 patients were treated in the corporate hospitals at the five different sites. Revenues for the period from January up to and including June stood at Euro 590.6 million. Earnings before interest, taxes, depreciation and amortisation (EBITDA) amounted to Euro 103.4 million including provisions of roughly Euro 41 million which had mainly been set aside for warranty claims from the sales transaction with Fresenius/Helios and were dissolved in the first six months of the financial year. The current financial figures are therefore not directly comparable with those of previous years due to these ongoing effects on the balance sheet. Outlook For financial year 2016 we expect revenues of Euro 1.17 billion to Euro 1.20 billion and earnings before interest, taxes, depreciation and amortisation (EBITDA) of between Euro 155 million and Euro 165 million. Positive and negative one-off effects, the size of which will be a low to medium two-digit million figure, will continue to influence the corporate results during this financial year as well and will partially cancel each other out. They mainly result from handling the transaction with Fresenius/ Helios, the initial consolidation and integration of the municipal hospital in Bad Neustadt, special budgets for innovation and e-health, unresolved accounting issues and setting up a substantial diagnostic and out-patient clinic at the university hospital in Marburg. Further legislative restrictions which will temporarily have a negative impact on the organic growth of the Company are currently to be expected in the largely regulated market environment in Germany. The Company must expect a drop in revenues of roughly 1 % for the current financial year arising, in particular, from the discounts on additional volume which were agreed in 2013; corresponding counteractive measures have already been introduced to neutralise the effects. "It remains to be seen how the new law to reform the structures of hospital care (Krankenhausstrukturgesetz - KHSG) will affect our business in the medium to long term. Individual aspects of state-of-the-art healthcare will in particular probably be subjected to a new basis for calculation weighted in accordance with the heavier burdens," CEO Dr. Martin Siebert stated. "We are prepared for this new challenge. We shall also be strong enough in the future to persevere successfully and profitably in a continuously demanding market environment." "With targeted investments the Company will further develop and strengthen its primary position to provide maximum cutting-edge medical care with a direct link to universities, focussing particularly on digitalisation and network medicine, the principal issues of the future. Together with the Company's campus concept all these initiatives form the basis of guaranteeing forward-looking healthcare which is constantly geared to patient needs," Siebert added. ************************************************************************** ************* RHÖN‐KLINIKUM AG is one of the largest healthcare providers in Germany. At five medical sites with a total of 5,400 beds we offer cutting-edge medical care with a direct link to universities and research institutes. Our top five key areas of treatment are cardiological and coronary disease, neurological disorders, oncology, lung diseases as well as orthopedic and accident surgery. A total of over 16,000 employees work for RHÖN-KLINIKUM AG. Our facilities are located in Bad Berka, Bad Neustadt/Saale, Frankfurt (Oder) and Giessen and Marburg. Further information is available at: www.rhoen-klinikum-ag.com. Your Contact Persons: RHÖN-KLINIKUM AG Achim Struchholz Group Division Head of Corporate Communication Schlossplatz 1 97616 Bad Neustadt / Saale Telephone: + 49 - 9771 65-1327 Facsimile: + 49 - 9771 65-1820 E-mail: [email protected] Dr. Kai G. Klinger Goup Division Head of Investor Relations & Group Financing Schlossplatz 1 97616 Bad Neustadt / Saale Telephone: + 49 - 9771 65-1318 Facsimile: + 49 - 9771 99-1736 E-mail: [email protected] --------------------------------------------------------------------------- 04.08.2016 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: RHÖN-KLINIKUM AG Salzburger Leite 1 97616 Bad Neustadt a.d.Saale Germany Phone: +49 (0)9771 - 65-0 Fax: +49 (0)9771 - 97 467 E-mail: [email protected] Internet: www.rhoen-klinikum-ag.com ISIN: DE0007042301 WKN: 704230 Indices: MDAX Listed: Regulated Market in Frankfurt (Prime Standard), Munich; Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 489315 04.08.2016


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 1.211,08 1.232,91 1.303,90 1.360,16 1.402,01 1.446,09 1.510,00
EBITDA1,2 97,82 125,54 125,33 80,23 101,16 105,65 107,50
EBITDA-Marge3 8,08 10,18 9,61 5,90 7,22 7,31
EBIT1,4 38,70 64,94 56,80 10,60 30,52 36,11 41,00
EBIT-Marge5 3,20 5,27 4,36 0,78 2,18 2,50 2,72
Jahresüberschuss1 36,74 51,19 44,48 2,46 30,23 26,94 35,00
Netto-Marge6 3,03 4,15 3,41 0,18 2,16 1,86 2,32
Cashflow1,7 80,30 49,50 47,30 113,30 97,50 41,30 0,00
Ergebnis je Aktie8 0,53 0,73 0,65 0,02 0,42 0,38 0,51
Dividende8 0,22 0,29 0,00 0,00 0,00 0,15 0,35
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: KPMG

INVESTOR-INFORMATIONEN
©boersengefluester.de
Rhön-Klinikum
WKN Kurs in € Einschätzung Börsenwert in Mio. €
704230 11,000 Halten 736,59
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
15,28 27,78 0,54 18,97
KBV KCV KUV EV/EBITDA
0,60 17,84 0,51 7,66
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,15 0,15 1,36 05.06.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
08.05.2024 08.08.2024 09.11.2023 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
4,99% -2,46% 10,00% -12,35%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu RHÖN-KLINIKUM AG  ISIN: DE0007042301 können Sie bei EQS abrufen


Pflegeeinrichtungen , 704230 , RHK , XETR:RHK